In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CeNeS Pharmaceuticals Inc.

Division of Paion AG

Latest From CeNeS Pharmaceuticals Inc.

Treating Traumatic Brain Injury

Past failures guide start-ups that seek to develop drugs for this silent epidemic, but will investors follow?


Scion Pharmaceuticals Inc.

David Farb, PhD never realized that his invention of automating the electrophysiology (EP) assay would become the basis for founding a new company. He engineered High-Throughput Electrophysiology (HTEP) purely for academic pursuits, but the patent caught the attention of Boston University's Community Technology Fund, Mark Carthy of Oxford Bioscience Partners, and Pravin Chaturvedi, PhD. After just three months of discussions, Farb, Carthy, and Chaturvedi decided that HTEP was an academic tool with industrial applications, so they founded Scion Pharmaceuticals Inc. in September 2001.

BioPharmaceutical Business Strategies

Alkermes' Incrementalism

Alkermes' success in creating a commercial product out of Genentech's growth hormone has taken it across a fundamental credibility gap all new drug delivery companies face. One result: an extraordinarily high valuation that has permitted it to raise plenty of cash. And it's using these assets--credibility, cash and valuation--to invest in programs which can bring it nearer term revenues and higher margins, in terms of new, accelerated, or risk-sharing deals. Indeed, it's even treating its current net-loss position as an asset, spending heavily now--which its profitable competitors can't, given their valuation-sensitive earnings constraints--and even signing complex deals to take its partners' expenses onto its own P&L, reimbursing itself with equity and downstream milestones. Moreover, it's shown itself, as in its acquisition of Advanced Inhalation Research, willing to dramatically expand its portfolio of technologies with work done on the outside. Alkermes also wants to develop products for its own account, though its strategy for commercializing them, while maintaining a strong delivery technology base, is unclear.

BioPharmaceutical Business Strategies

The Tantalizing Market for Stroke Devices

A potentially enormous market without therapeutic options is attracting a lot of new technology developesr and venture capital to stroke. But the opportunity for clot-busting approaches is limited and getting enough patients for clinical trials is tough. In a market full of unknowns, one thing is certain: the ultimate goal of any stroke therapy is to avoid neurological deficit.

Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Cambridge Neuroscience Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Paion AG
  • Senior Management
  • Harry W Wilcox, Pres. & CEO
    Harry W Wilcox III, SVP, Fin. & Bus. Dev. & CFO
    Jerry Williamson, Dir., Mktg.
    Robert N McBurney, PhD, SVP, Research & CSO
  • Contact Info
  • CeNeS Pharmaceuticals Inc.
    Phone: (617) 225-0600
    One Kendall Square, Bldg 700
    Cambridge, MA 02139